← Back
Data updated: Jul 17, 2026
Pharming Americas BV
Biotech Pharmaceuticals
Pharming Americas BV is a biotechnology company with 1 FDA-approved products.
2014
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics
Upcoming FDA Decisions
Full Calendar → Oct 24, 2026 — separate
Pharming Americas BV's Key Drugs
Pharming Americas BV's core commercial portfolio centers on Ruconest — its most strategically important drugs approved in the last 15 years.
Pharming Americas BV's Recent FDA Approvals
New NDA/BLA approvals for Pharming Americas BV over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
Pharming Americas BV's Therapeutic Areas
Disease areas where Pharming Americas BV has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
Pharming Americas BV Pipeline Snapshot
Active clinical trials for Pharming Americas BV across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Ruconest leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-07-15
- Latest
- 2014-07-15
- Applications
- 1